She most recently served as the chief scientific officer at Gritstone since 2016. Prior to Gritstone, from 2009 to 2016, Dr. Jooss was the head of cancer immuno-therapeutics at Pfizer, Inc., where she was also a member of the vaccine immuno-therapeutics leadership team. Prior to joining Pfizer, Dr. Jooss served as VP of research from 2005 to 2009 and as Sr. director of research at Cell Genesys Inc. from 2001 to 2005. She is on the editorial board of Molecular Therapy and the Journal of Gene Medicine and is a member of the Immunology and Educational Committee of the American Society of Gene & Cell Therapy. Dr. Jooss serves on the board of directors of Fate Therapeutics, Inc. Dr. Jooss received her diploma in theoretical medicine and a Ph.D. in molecular biology from the University of Marburg/Germany and performed postgraduate work in gene therapy and immunology at the University of Pennsylvania.
Self-Amplifying mRNA Multi-antigen Coronavirus Vaccine
The talk will cover the generation of chimeric antigen coronavirus vaccines to drive broad and potent T-cell responses against viral genes beyond Spike in addition to high neutralizing antibodies to Spike. The vaccine platform is a self-amplifying RNA (samRNA) which offers a potentially dose sparing vaccine opportunity to drive robust immune responses in humans.